SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Name:
mdz246.142.pdf
Size:
81.73Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Affiliation
Medical Oncology, Hopital Saint-Antoine, Paris,Issue Date
2019
Metadata
Show full item recordCitation
Andre T, Saunders MP, Kanehisa A, Gandossi E, Fougeray R, Causse-Amellal N, et al. 665TiP SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy. Annals of Oncology. 2019;30(Supplement_5):250.Journal
Annals of OncologyDOI
10.1093/annonc/mdz246.142Additional Links
https://dx.doi.org/10.1093/annonc/mdz246.142Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz246.142